FDAsafety guidance66% confidence
FDA TA — ANDA220499
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Alembic Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA220499. Sponsor: ALEMBIC PHARMACEUTICALS LIMITED. Submission status: TA. Submission type: ORIG. Review priority: STANDARD.
Supporting Context
- Therapeutic area
- Not specified
- Sub-indication
- General
Related signal: Alembic Pharmaceuticals submits ANDA220499 for FDA review